SCH772984 has shown promising results in a panel of melanoma cell lines, including cells with innate or acquired resistance to vemurafenib, cells with BRAF/NRAS double mutations or NRAS mutations (Morris et al., 2013; Wong et al., 2014) (NCT02457793). Here, NRAS is linked to melanoma.